Standpoint Research Starts Amgen (AMGN) at Buy; Potential Upside Through 2013
Tweet Send to a Friend
Standpoint Research initiates coverage on Amgen (NASDAQ: AMGN) with a Buy. PT $66.
Standpoint analyst, Ronnie Moas, said, "In our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Standpoint analyst, Ronnie Moas, said, "In our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
